Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

毛霉病 医学 临床终点 两性霉素B 不利影响 内科学 外科 毛孔 临床试验 皮肤病科 抗真菌
作者
Francisco M. Marty,Luis Ostrosky‐Zeichner,Oliver A. Cornely,Kathleen M. Mullane,John R. Perfect,George R. Thompson,George Alangaden,Janice M. Brown,David N. Fredricks,Werner Heinz,Raoul Herbrecht,Н Н Климко,G. A. Klyasova,Johan Maertens,Sameer Melinkeri,Ilana Oren,Peter G. Pappas,Zdeněk Ráčil,Galia Rahav,Rodrigo Ribeiro dos Santos
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:16 (7): 828-837 被引量:629
标识
DOI:10.1016/s1473-3099(16)00071-2
摘要

Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active in vitro and in animal models against moulds of the order Mucorales. We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis.In a single-arm open-label trial (VITAL study), adult patients (≥18 years) with invasive fungal disease caused by rare fungi, including mucormycosis, were recruited from 34 centres worldwide. Patients were given isavuconazole 200 mg (as its intravenous or oral water-soluble prodrug, isavuconazonium sulfate) three times daily for six doses, followed by 200 mg/day until invasive fungal disease resolution, failure, or for 180 days or more. The primary endpoint was independent data review committee-determined overall response-ie, complete or partial response (treatment success) or stable or progressive disease (treatment failure)-according to prespecified criteria. Mucormycosis cases treated with isavuconazole as primary treatment were matched with controls from the FungiScope Registry, recruited from 17 centres worldwide, who received primary amphotericin B-based treatment, and were analysed for day-42 all-cause mortality. VITAL is registered with ClinicalTrials.gov, number NCT00634049. FungiScope is registered with ClinicalTrials.gov, number NCT01731353.Within the VITAL study, from April 22, 2008, to June 21, 2013, 37 patients with mucormycosis received isavuconazole for a median of 84 days (IQR 19-179, range 2-882). By day 42, four patients (11%) had a partial response, 16 (43%) had stable invasive fungal disease, one (3%) had invasive fungal disease progression, three (8%) had missing assessments, and 13 (35%) had died. 35 patients (95%) had adverse events (28 [76%] serious). Day-42 crude all-cause mortality in seven (33%) of 21 primary-treatment isavuconazole cases was similar to 13 (39%) of 33 amphotericin B-treated matched controls (weighted all-cause mortality: 33% vs 41%; p=0·595).Isavuconazole showed activity against mucormycosis with efficacy similar to amphotericin B. Isavuconazole can be used for treatment of mucormycosis and is well tolerated.Astellas Pharma Global Development, Basilea Pharmaceutica International.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
福尔摩云完成签到,获得积分10
1秒前
无辜的秀完成签到,获得积分10
2秒前
Charles完成签到,获得积分10
4秒前
hao发布了新的文献求助10
4秒前
小嘎发布了新的文献求助10
4秒前
ABin完成签到,获得积分10
6秒前
Jasper应助qixiaoqi采纳,获得10
6秒前
FangyingTang完成签到 ,获得积分10
7秒前
金枪鱼子完成签到,获得积分10
7秒前
theyoung发布了新的文献求助10
7秒前
8秒前
量子星尘发布了新的文献求助10
8秒前
赘婿应助liu采纳,获得10
8秒前
小马甲应助清仔采纳,获得10
8秒前
8秒前
luoyue完成签到,获得积分10
8秒前
yuan发布了新的文献求助10
9秒前
科研通AI5应助JR采纳,获得30
9秒前
10秒前
海阔天空发布了新的文献求助10
11秒前
SYLH应助WangZhen采纳,获得10
11秒前
票子发布了新的文献求助10
11秒前
苹果柜子完成签到 ,获得积分10
11秒前
活泼的平灵完成签到,获得积分10
12秒前
愤怒的咖啡完成签到,获得积分10
12秒前
愉快的银耳汤完成签到,获得积分10
13秒前
又又完成签到,获得积分10
14秒前
ypres完成签到 ,获得积分10
15秒前
15秒前
15秒前
zzzk完成签到 ,获得积分10
15秒前
酒精过敏完成签到,获得积分10
15秒前
席冥完成签到,获得积分10
17秒前
18秒前
搜集达人应助可乐采纳,获得10
18秒前
19秒前
清仔发布了新的文献求助10
19秒前
kevin发布了新的文献求助10
20秒前
飘逸怜菡完成签到 ,获得积分10
20秒前
单身的钧完成签到,获得积分10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038619
求助须知:如何正确求助?哪些是违规求助? 3576294
关于积分的说明 11375058
捐赠科研通 3306084
什么是DOI,文献DOI怎么找? 1819374
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066